To design an accelerated method to evaluate thymopentin release from PLGA microspheres in vitro. Microspheres were prepared by double emulsion technique, using poly（lactide-co-glycolide） （PLGA） as carrier. At high...To design an accelerated method to evaluate thymopentin release from PLGA microspheres in vitro. Microspheres were prepared by double emulsion technique, using poly（lactide-co-glycolide） （PLGA） as carrier. At higher medium temperature （45℃, 50℃ and 55℃）, an accelerated release testing in short time was studied and correlated with the conventional release （37℃） in vitro. The release in vitro of thymopentin from PLGA microspheres at 45 ℃, 50℃ and 55℃ was significantly accelerated （P 〈 0.05）. In particular, at 50℃, an accelerated release （30 h） of the hydrophilic peptide from the PLGA matrix was achieved and correlated well with the conventional release （30 d）. An accelerated release testing in vitro at higher temperature could be used to monitor thymopentin release from PLGA microspheres.展开更多
目的对比分析PCD方案(硼替佐米+环磷酰胺+地塞米松)与VAD方案(长春新碱+表阿霉素+地塞米松)治疗以早期肾损伤为主的多发性骨髓瘤的近期疗效,以期提供最佳治疗方案。方法回顾性分析2012年12月至2016年3月于青海省人民医院血液科初次诊治...目的对比分析PCD方案(硼替佐米+环磷酰胺+地塞米松)与VAD方案(长春新碱+表阿霉素+地塞米松)治疗以早期肾损伤为主的多发性骨髓瘤的近期疗效,以期提供最佳治疗方案。方法回顾性分析2012年12月至2016年3月于青海省人民医院血液科初次诊治为多发性骨髓瘤(以早期肾损伤为主)的180例患者的临床资料,根据治疗方案不同分为PCD组及VAD组,其中PCD组100例,VAD组80例,分析两组患者的治疗效果及毒副反应。结果 PCD组GFR[(98.12±8.88)m L/min]与VAD组[(78.98±9.650)m L/min]比较明显升高,PCD组Crcl>50 m L/min(60.00%)与VAD组(35.00%)比较明显增多,Crcl<30 m L/min(5.00%)与VAD组(18.00%)比较则明显减小,差异均有统计学意义(P<0.05)。PCD组治疗后部分反应及以上有效率(50.00%)明显高于VAD组(12.50%),且差异具有统计学意义(P<0.05)。PCD组毒性总反应率(55.00%)略高于VAD组(45.00%),但差异无统计学意义(P>0.05),但PCD组周围神经炎发生率(40.00%)明显高于VAD组(15.00%),而VAD组血细胞减少或缺乏率(30.00%)高于PCD组(5.00%),两者差异均具有统计学意义(P<0.05)。结论 PCD方案治疗以早期肾损伤为主的多发性骨髓瘤的近期疗效明显优于VAD方案,但须注意控制剂量,谨防周围神经毒性的发生。展开更多
文摘To design an accelerated method to evaluate thymopentin release from PLGA microspheres in vitro. Microspheres were prepared by double emulsion technique, using poly（lactide-co-glycolide） （PLGA） as carrier. At higher medium temperature （45℃, 50℃ and 55℃）, an accelerated release testing in short time was studied and correlated with the conventional release （37℃） in vitro. The release in vitro of thymopentin from PLGA microspheres at 45 ℃, 50℃ and 55℃ was significantly accelerated （P 〈 0.05）. In particular, at 50℃, an accelerated release （30 h） of the hydrophilic peptide from the PLGA matrix was achieved and correlated well with the conventional release （30 d）. An accelerated release testing in vitro at higher temperature could be used to monitor thymopentin release from PLGA microspheres.
文摘目的对比分析PCD方案(硼替佐米+环磷酰胺+地塞米松)与VAD方案(长春新碱+表阿霉素+地塞米松)治疗以早期肾损伤为主的多发性骨髓瘤的近期疗效,以期提供最佳治疗方案。方法回顾性分析2012年12月至2016年3月于青海省人民医院血液科初次诊治为多发性骨髓瘤(以早期肾损伤为主)的180例患者的临床资料,根据治疗方案不同分为PCD组及VAD组,其中PCD组100例,VAD组80例,分析两组患者的治疗效果及毒副反应。结果 PCD组GFR[(98.12±8.88)m L/min]与VAD组[(78.98±9.650)m L/min]比较明显升高,PCD组Crcl>50 m L/min(60.00%)与VAD组(35.00%)比较明显增多,Crcl<30 m L/min(5.00%)与VAD组(18.00%)比较则明显减小,差异均有统计学意义(P<0.05)。PCD组治疗后部分反应及以上有效率(50.00%)明显高于VAD组(12.50%),且差异具有统计学意义(P<0.05)。PCD组毒性总反应率(55.00%)略高于VAD组(45.00%),但差异无统计学意义(P>0.05),但PCD组周围神经炎发生率(40.00%)明显高于VAD组(15.00%),而VAD组血细胞减少或缺乏率(30.00%)高于PCD组(5.00%),两者差异均具有统计学意义(P<0.05)。结论 PCD方案治疗以早期肾损伤为主的多发性骨髓瘤的近期疗效明显优于VAD方案,但须注意控制剂量,谨防周围神经毒性的发生。
